

Alfredo Falcone

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/402071/alfredo-falcone-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

377 papers	20,604 citations	65 h-index	136 g-index
409 ext. papers	24,494 ext. citations	6.2 avg, IF	6 L-index

#	Paper	IF	Citations
377	A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.. <i>Npj Breast Cancer</i> , 2022 , 8, 33	7.8	
376	Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. <i>Cancer Treatment Reviews</i> , 2021 , 102, 102301	14.4	3
375	Detailing the ultrastructure's increase of prion protein in pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2021 , 27, 7324-7339	5.6	0
374	and Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients. <i>Oncology Research</i> , 2021 , 28, 631-644	4.8	4
373	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1153-1160	6.1	0
372	BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1386-1395	9.7	3
371	Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade. <i>Journal of the Endocrine Society</i> , 2021 , 5, bvab093	0.4	1
370	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021 , 11, 12191	4.9	0
369	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021 , 150, 133-142	7.5	1
368	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	2
367	Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer. <i>Future Oncology</i> , 2021 , 17, 2315-2324	3.6	0
366	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021 , 125, 839-845	8.7	2
365	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021 , 124, 183-190	8.7	5
364	Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients. <i>Clinical and Experimental Medicine</i> , 2021 , 21, 149-159	4.9	2
363	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021 , 92, 102135	14.4	2
362	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1174-1183	12.9	7
361	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021 , 26, 302-309	5.7	4

360	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2021 , 21, 285-295	3.5	0
359	Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). <i>Cancers</i> , 2021 , 13,	6.6	1
358	Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4
357	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. <i>JAMA Oncology</i> , 2021 , 7, 1529-1535	13.4	13
356	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
355	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021 , 153, 16-26	7.5	1
354	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021 , 155, 73-84	7.5	3
353	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	4
352	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020 , 135, 78-88	7.5	5
351	Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. <i>ESMO Open</i> , 2020 , 5, e000698	6	7
350	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2020 , 21, 497-507	21.7	98
349	Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	14
348	A Model of a Zebrafish Avatar for Co-Clinical Trials. <i>Cancers</i> , 2020 , 12,	6.6	24
347	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 685-698	5.1	2
346	TRIBE2 results and toxicity - Authors' reply. <i>Lancet Oncology, The</i> , 2020 , 21, e300-e301	21.7	
345	Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center. <i>In Vivo</i> , 2020 , 34, 2061-2066	2.3	
344	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. <i>Cancers</i> , 2020 , 12,	6.6	2
343	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 319-326	5.4	8

342	Application of the ESR iGuide clinical decision support system to the imaging pathway of patients with hepatocellular carcinoma and cholangiocarcinoma: preliminary findings. <i>Radiologia Medica</i> , 2020 , 125, 531-537	6.5	15
341	Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications. <i>Frontiers in Oncology</i> , 2020 , 10, 64	5.3	4
340	First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. <i>Future Oncology</i> , 2020 , 16, 21-29	3.6	16
339	Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer. <i>International Journal of Cancer</i> , 2020 , 146, 2652-2654	7.5	3
338	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. <i>Advances in Therapy</i> , 2020 , 37, 1145-1155	4.1	52
337	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. <i>Targeted Oncology</i> , 2020 , 15, 115-126	5	11
336	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020 , 131, 89-97	7.5	3
335	HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer. <i>Oncologist</i> , 2020 , 25, 886-893	5.7	12
334	The Role of Anti-Angiogenics in Pre-Treated Metastatic -Mutant Colorectal Cancer: A Pooled Analysis. <i>Cancers</i> , 2020 , 12,	6.6	9
333	FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4015-4015	2.2	7
332	Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer service. <i>Biomedical Reports</i> , 2020 , 12, 199-203	1.8	
331	Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. <i>World Journal of Gastroenterology</i> , 2020 , 26, 2792-2809	5.6	12
330	Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 493-501	4.9	5
329	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2020 , 139, 81-89	7.5	3
328	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020 , 138, 1-10	7.5	9
327	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer 2020 , 8,		4
326	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020 , 20, 683	4.8	26
325	First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?. <i>European Journal of Cancer</i> , 2020 , 137, 108-116	7.5	6

324	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2146-2154	6.1	8
323	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2020 , JCO2001225	2.2	52
322	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. <i>Cancers</i> , 2020 , 12,	6.6	17
321	Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells. <i>Investigational New Drugs</i> , 2020 , 38, 92-98	4.3	3
320	Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2020 , 20, e89-e98	3	6
319	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 191-199.e6	3.8	10
318	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019 , 2, e1911750	10.4	1
317	Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 269-279.e5	3.8	3
316	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e394-e401	3.8	7
315	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. <i>Pharmacogenomics Journal</i> , 2019 , 19, 455-464	3.5	3
314	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 420-435	21.7	110
313	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , 2019 , 19, 465-472	3.5	11
312	Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019 , 51, 1113-1122	16.2	164
311	AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer. <i>BJU International</i> , 2019 , 124, 693	5.6	19
310	Interprofessional spiritual care in oncology: a literature review. <i>ESMO Open</i> , 2019 , 4, e000465	6	43
309	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2019 , 20, 849-861	21.7	201
308	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 116-124	3.8	5
307	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. <i>European Journal of Cancer</i> , 2019 , 111, 138-147	7.5	3

306	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. <i>International Journal of Cancer</i> , 2019 , 145, 2082-2090	7.5	0
305	Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019 , 4, e000489	6	8
304	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. <i>Biochemical Pharmacology</i> , 2019 , 164, 94-105	6	9
303	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019 , 19, 556-563	3.5	20
302	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019 , 109, 175-182	7.5	17
301	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019 , 110, 32-41	7.5	12
300	Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. <i>British Journal of Cancer</i> , 2019 , 120, 522-526	8.7	8
299	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-14	3.6	6
298	Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study. <i>Cancers</i> , 2019 , 11,	6.6	4
297	Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 57-62	4.4	49
296	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1268-1275	13.4	37
295	Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. <i>European Journal of Cancer</i> , 2019 , 123, 146-154	7.5	29
294	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. <i>ESMO Open</i> , 2019 , 4, e000496	6.96	0
293	Atypical Mutations in Metastatic Colorectal Cancer.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-11	3.6	
292	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIb CONSIGN Study. <i>Oncologist</i> , 2019 , 24, 185-192	5.7	52
291	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e8-e19	3.8	9
290	Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 343-350	13.4	134
289	The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. <i>Pharmacogenomics</i> , 2019 , 20, 49-68	2.6	18

288	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. <i>British Journal of Cancer</i> , 2018 , 118, 820-824	8.7	117
287	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2018 , 36, 709-714	4.3	5
286	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018 , 18, 435-446	2.2	9
285	Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e471-e488	3.8	4
284	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 638-648	9.7	63
283	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 529-536	13.4	51
282	EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. <i>Cancer Biomarkers</i> , 2018 , 21, 731-741	3.8	7
281	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e395-e414	3.8	16
280	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018 , 118, 955-965	8.7	10
279	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018 , 18, 623-632	3.5	4
278	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018 , 3, e000403	6	15
277	A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. <i>Colorectal Cancer</i> , 2018 , 7, CRC01	0.8	2
276	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2018 , 392, 123-133	40	624
275	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. <i>PLoS ONE</i> , 2018 , 13, e0193640	3.7	3
274	Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. <i>Cancer Treatment Reviews</i> , 2018 , 69, 90-100	14.4	11
273	Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12007-12007	2.2	10
272	and genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018 , 9, 7859-7866	3.3	18
271	Current status and perspectives in immunotherapy for metastatic melanoma. <i>Oncotarget</i> , 2018 , 9, 12452-12470	5.3	95

270	Integrated safety summary for trifluridine/tipiracil (TAS-102). <i>Anti-Cancer Drugs</i> , 2018 , 29, 89-96	2.4	8
269	A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , 2018 , 24, 784-793	12.9	14
268	Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>Eur Urol</i> 2017;71:680-7. <i>European Urology</i> , 2018 , 73, e11-e12	10.2	
267	Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation. <i>Future Science OA</i> , 2018 , 4, FSO346	2.7	1
266	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. <i>European Journal of Cancer</i> , 2018 , 103, 205-213	7.5	9
265	BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases. <i>JAMA Surgery</i> , 2018 , 153, 1162-1163	5.4	
264	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018 , 23, 1178-1187	5.7	31
263	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018 , 100, 35-45	7.5	20
262	Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. <i>Pharmacogenomics Journal</i> , 2017 , 17, 258-264	3.5	55
261	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017 , 116, 318-323	8.7	20
260	First-line therapy for mCRC - the influence of primary tumour location on the therapeutic algorithm. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 113	19.4	16
259	Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients. <i>Breast</i> , 2017 , 31, 186-191	3.6	7
258	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. <i>British Journal of Cancer</i> , 2017 , 117, 315-321	8.7	15
257	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017 , 82, 237-246	7.5	30
256	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	126
255	Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. <i>International Journal of Cancer</i> , 2017 , 141, 383-392	7.5	5
254	Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 114, 24-32	7	13
253	Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months. <i>Experimental Hematology and Oncology</i> , 2017 , 6, 6	7.8	25

252	Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , 2017 , 77, 13-20	7.5	15
251	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2017 , 73, 74-84	7.5	32
250	Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. <i>Annals of Oncology</i> , 2017 , 28, 3009-3014	10.3	48
249	Adjuvant chemoradiotherapy (gemcitabine-based) in pancreatic adenocarcinoma: the Pisa University experience. <i>Tumori</i> , 2017 , 103, 577-582	1.7	1
248	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1929-1937	2.2	28
247	Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer. <i>Translational Gastroenterology and Hepatology</i> , 2017 , 2, 11	5.2	
246	Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. <i>Scientific Reports</i> , 2017 , 7, 7931	4.9	43
245	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017 , 123, 4506-4514	6.4	14
244	Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. <i>Annals of Oncology</i> , 2017 , 28, 2780-2785	10.3	19
243	Proxies of quality of life in metastatic colorectal cancer: analyses in the RECURSE trial. <i>ESMO Open</i> , 2017 , 2, e000261	6	16
242	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017 , 2, e000241	6	6
241	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1688-1700	21.7	328
240	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017 , 82, 16-24	7.5	28
239	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017 , 17, 408	4.8	20
238	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017 , 28, 555-561	10.3	32
237	Impact of a supportive care service for cancer outpatients: management and reduction of hospitalizations. Preliminary results of an integrated model of care. <i>Supportive Care in Cancer</i> , 2017 , 25, 209-212	3.9	13
236	The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>European Urology</i> , 2017 , 71, 680-687	10.2	163
235	Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study. <i>Annals of Oncology</i> , 2017 , 28, iii10	10.3	6

234	Novel prognostic markers for epithelioid malignant pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20028-e20028	2.2	2
233	Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation. <i>PLoS ONE</i> , 2017 , 12, e0182818	3.7	13
232	Patients with NSCLC may display a low ratio of p.T790M activating EGFR mutations in plasma at disease progression: implications for personalised treatment. <i>Oncotarget</i> , 2017 , 8, 86056-86065	3.3	8
231	Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. <i>Oncotarget</i> , 2017 , 8, 13611-13619	3.3	66
230	Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. <i>Anticancer Research</i> , 2017 , 37, 315-319	2.3	16
229	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017 , 49, 834-845	5.2	9
228	Variations of circulating KRAS amount as a biomarker to monitor chemotherapy response in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15794-e15794	2.2	1
227	Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2016 , 34, 760-770	4.3	21
226	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 988-94	5.7	72
225	Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. <i>Oncology</i> , 2016 , 91, 311-316	3.6	8
224	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology</i> , 2016 , 17, 1709-1719	21.7	258
223	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2016 , 6, 25195	4.9	19
222	Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1740-5	6.1	7
221	Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. <i>Future Oncology</i> , 2016 , 12, 901-8	3.6	13
220	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. <i>Annals of Oncology</i> , 2016 , 27, 843-9	10.3	36
219	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016 , 114, 30-6	8.7	39
218	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 144-50	2.2	76
217	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6987-7005	5.6	52

216	First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. <i>International Journal of Cancer</i> , 2016 , 139, 938-45	7.5	34
215	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1386-422	10.3	1683
214	Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. <i>Oncology</i> , 2016 , 91, 283-288	3.6	1
213	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). <i>ESMO Open</i> , 2016 , 1, e000111	6	22
212	A still missing piece of the FIRE-3 puzzle. <i>Lancet Oncology, The</i> , 2016 , 17, e515	21.7	
211	Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'. <i>British Journal of Cancer</i> , 2016 , 114, e8	8.7	1
210	Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3822-3823	2.2	23
209	Primary tumor location as a prognostic factor in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	298
208	First-line chemotherapy for mCRCB review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 607-19	19.4	106
207	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology, The</i> , 2015 , 16, 937-48	21.7	240
206	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015 , 26, 2092-7	10.3	110
205	Randomized trial of TAS-102 for refractory metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 1909-19	59.2	720
204	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. <i>British Journal of Cancer</i> , 2015 , 112, 1921-8	8.7	111
203	Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. <i>Annals of Oncology</i> , 2015 , 26, 1188-1194	10.3	112
202	Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. <i>Annals of Oncology</i> , 2015 , 26, 2450-6	10.3	20
201	Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2374-81	6.1	3
200	TAS-102 for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1283-92	3.5	8
199	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncology, The</i> , 2015 , 16, 1306-15	21.7	593

198	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015 , 26, 2503	10.3	15
197	MRI tumor volume reduction rate vs tumor regression grade in the pre-operative re-staging of locally advanced rectal cancer after chemo-radiotherapy. <i>European Journal of Radiology</i> , 2015 , 84, 2438-43	4.7	23
196	Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2015 , 11, 323-31	3.6	8
195	Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015 , 136, 83-90	7.5	92
194	Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. <i>Journal of Clinical Oncology</i> , 2015 , 33, 22-8	2.2	69
193	Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2015 , 15, 69-76	3.5	24
192	TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply. <i>Lancet Oncology, The</i> , 2015 , 16, e578-9	21.7	
191	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 156	12.8	40
190	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. <i>BMC Cancer</i> , 2015 , 15, 874	4.8	8
189	Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifen. <i>Tumori</i> , 2015 , 101, e24-8	1.7	3
188	FOLFOXIRI and bevacizumab for metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 291-2	59.2	10
187	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015 , 21, 795-801	50.5	557
186	A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. <i>Journal of Gastrointestinal Cancer</i> , 2015 , 46, 201-11	1.6	143
185	First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 156-66	7	50
184	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3510-3510	2.2	6
183	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 657-657	2.2	5
182	Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients. <i>Oncotarget</i> , 2015 , 6, 28743-54	3.3	16
181	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. <i>Oncotarget</i> , 2015 , 6, 33982-92	3.3	39

180	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015 , 6, 31604-12	3.3	27
179	Dedicated supportive care team at the oncology unit: a model of simultaneous care for cancer patients. <i>Supportive Care in Cancer</i> , 2014 , 22, 867-8	3.9	6
178	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. <i>British Journal of Cancer</i> , 2014 , 110, 2165-9	8.7	56
177	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1609-18	59.2	663
176	Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2014 , 14, 453-68	3.8	16
175	KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting. <i>PLoS ONE</i> , 2014 , 9, e85897	3.7	10
174	Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. <i>Pharmacogenomics</i> , 2014 , 15, 1985-99	2.6	13
173	Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. <i>Future Oncology</i> , 2014 , 10, 285-304	3.6	11
172	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. <i>Pharmacogenomics</i> , 2014 , 15, 1701-15	15	4
171	and genotyping of synchronous colorectal carcinomas. <i>Oncology Letters</i> , 2014 , 7, 1532-1536	2.6	5
170	Not only chemotherapy in the second-line treatment of metastatic gastric cancer. <i>Annals of Oncology</i> , 2014 , 25, 544-5	10.3	4
169	Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. <i>Cancer</i> , 2014 , 120, 3923-31	6.4	30
168	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Annals of Oncology</i> , 2014 , 25, 1373-1378	10.3	61
167	Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. <i>Pharmacogenomics Journal</i> , 2014 , 14, 322-7	3.5	10
166	Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review. <i>World Journal of Gastroenterology</i> , 2014 , 20, 6081-91	5.6	22
165	Biomarkers and response to bevacizumab--letter. <i>Clinical Cancer Research</i> , 2014 , 20, 1056-7	12.9	8
164	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014 , 9, 205-14	5	22
163	Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3596-3596	2.2	4

162	The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients 2014 , 135-142		
161	Electrochemotherapy and its controversial results in patients with head and neck cancer. <i>Anticancer Research</i> , 2014 , 34, 967-72	2.3	11
160	Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 188-94	3.8	21
159	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013 , 381, 303-12	4 ⁰	17 ⁸³
158	Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. <i>British Journal of Cancer</i> , 2013 , 108, 2549-56	8.7	45
157	Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). <i>European Urology</i> , 2013 , 63, 254-61	10.2	24
156	The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. <i>Annals of Oncology</i> , 2013 , 24, 734-41	10.3	72
155	Supportive care and not only palliative care in the route of cancer patients. <i>Supportive Care in Cancer</i> , 2013 , 21, 657-8	3.9	5
154	Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2013 , 49, 1501-8	7.5	15
153	Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. <i>Cancer Biology and Therapy</i> , 2013 , 14, 467-8	4.6	5
152	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). <i>Annals of Oncology</i> , 2013 , 24, 2062-7	10.3	74
151	Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'. <i>British Journal of Cancer</i> , 2013 , 109, 3129-30	8.7	2
150	VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. <i>British Journal of Cancer</i> , 2013 , 109, 957-64	8.7	36
149	FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group. <i>Annals of Oncology</i> , 2013 , 24, iv21	10.3	4
148	Conference Scene: Annual Meeting of the American Society of Clinical Oncology. <i>Colorectal Cancer</i> , 2013 , 2, 401-404	0.8	
147	Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2013 , 2, 411-417	0.8	0
146	Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. <i>PLoS ONE</i> , 2013 , 8, e66774	3.7	55
145	Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. <i>Anticancer Research</i> , 2013 , 33, 3487-94	2.3	50

144	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. <i>Cancer</i> , 2012 , 118, 1523-32	6.4	32
143	PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. <i>Journal of Cellular Physiology</i> , 2012 , 227, 927-33	7	5
142	Resectable liver metastases from colorectal cancer: where we are now and where do we go from here?. <i>Colorectal Cancer</i> , 2012 , 1, 397-411	0.8	
141	Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. <i>Annals of Oncology</i> , 2012 , 23, 1706-12	10.3	29
140	EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. <i>Cancer and Metastasis Reviews</i> , 2012 , 31, 753-61	9.6	131
139	Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. <i>Annals of Oncology</i> , 2012 , 23, 2313-2318	10.3	129
138	Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 71-6	3.8	15
137	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. <i>Annals of Oncology</i> , 2012 , 23, 1370-1371	10.3	7
136	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 1207-1213	10.3	36
135	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 153-160	1	
134	. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 263-271	1	1
133	High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. <i>PLoS ONE</i> , 2012 , 7, e49145	3.7	57
132	Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 1187-96	4.9	24
131	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. <i>Angiogenesis</i> , 2012 , 15, 275-86	10.6	53
130	High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. <i>Oncologist</i> , 2012 , 17, 823-9	5.7	67
129	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. <i>Annals of Oncology</i> , 2012 , 23, 2072-2077	10.3	82
128	Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. <i>Annals of Oncology</i> , 2012 , 23, 135-141	10.3	60
127	Prognostic value of CD133 caused by mutant K-Ras and B-Raf--letter. <i>Clinical Cancer Research</i> , 2012 , 18, 4473; author reply 4474	12.9	

126	A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients. <i>Oncology</i> , 2012 , 82, 75-82	3.6	7
125	Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3540-3540	2.2	1
124	Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA385-LBA385	2.2	25
123	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011 , 11, 247	4.8	61
122	Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. <i>British Journal of Cancer</i> , 2011 , 104, 1786-90	8.7	55
121	Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2011 , 104, 1262-9	8.7	77
120	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 519-31	5.4	3
119	Anti-HER agents in gastric cancer: from bench to bedside. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 8, 369-83	24.2	61
118	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 78, 243-51	7	26
117	Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). <i>Current Cancer Drug Targets</i> , 2011 , 11, 123-9	2.8	36
116	Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches. <i>Future Oncology</i> , 2011 , 7, 1299-323	3.6	12
115	Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 21-30	9.7	131
114	Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. <i>Annals of Oncology</i> , 2011 , 22, 1141-1146	10.3	46
113	Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. <i>Annals of Oncology</i> , 2011 , 22, 482-4	10.3	8
112	Faithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3487-8; author reply 3488-90	2.2	12
111	Should oncologists be aware in their clinical practice of KRAS molecular analysis?. <i>Journal of Clinical Oncology</i> , 2011 , 29, e206-7; author reply e208-9	2.2	15
110	Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. <i>Pharmacogenomics</i> , 2011 , 12, 159-70	2.6	58
109	Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?. <i>British Journal of Cancer</i> , 2010 , 102, 1076-1077	8.7	1

108	Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. <i>Pharmacogenomics</i> , 2010 , 11, 1247-56	2.6	5
107	High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. <i>Annals of Oncology</i> , 2010 , 21, 1565	10.3	32
106	Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?. <i>Annals of Oncology</i> , 2010 , 21, 181	10.3	2
105	Palliative treatment of unresectable metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 63-77	4	16
104	Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. <i>Journal of Clinical Oncology</i> , 2010 , 28, e221-2; author reply e223-5	2.2	21
103	Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"? <i>Journal of Clinical Oncology</i> , 2010 , 28, e173-4; author reply e175-6	2.2	3
102	MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. <i>Cancer Research</i> , 2010 , 70, 4528-38	10.1	361
101	Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 190-1	19.4	3
100	Second-line treatment for non-small-cell lung cancer: one size does not fit all. <i>Clinical Lung Cancer</i> , 2010 , 11, 320-7	4.9	10
99	Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 581-93	6.1	59
98	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. <i>Lancet Oncology</i> , 2010 , 11, 845-52	21.7	204
97	Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. <i>Pharmacogenomics Journal</i> , 2010 , 10, 458-64	3.5	102
96	Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010 , 29, 58	12.8	41
95	Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients?. <i>Drugs and Aging</i> , 2010 , 27, 689-96	4.7	18
94	Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. <i>Annals of Oncology</i> , 2010 , 21, 2382-2389	10.3	78
93	Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. <i>Current Cancer Drug Targets</i> , 2010 , 10, 37-45	2.8	8
92	Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 559-66	3.5	5
91	Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?. <i>EPMA Journal</i> , 2010 , 1, 495-502	8.8	18

90	Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. <i>International Journal of Cancer</i> , 2010 , 127, 1941-7	7.5	56
89	Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. <i>Journal of the American Geriatrics Society</i> , 2010 , 58, 986-8	5.6	23
88	Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009 , 1, 167-81	5.4	6
87	Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. <i>Pharmacogenomics Journal</i> , 2009 , 9, 78-84	3.5	18
86	Do we need biopsies of metastases for colorectal cancer patients?. <i>British Journal of Cancer</i> , 2009 , 101, 374-5; author reply 376	8.7	2
85	Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. <i>British Journal of Cancer</i> , 2009 , 100, 881-7	8.7	139
84	A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009 , 100, 1720-4	8.7	27
83	Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. <i>Pharmacogenomics</i> , 2009 , 10, 1225-9	2.6	6
82	Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 945-9	5.4	12
81	Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?. <i>Annals of Oncology</i> , 2009 , 20, 790-1	10.3	5
80	Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 4954-62	12.9	74
79	Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. <i>Annals of Surgery</i> , 2009 , 249, 420-5	7.8	192
78	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. <i>BMC Cancer</i> , 2009 , 9, 303	4.8	60
77	Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. <i>European Journal of Pharmacology</i> , 2009 , 619, 8-14	5.3	28
76	VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. <i>International Journal of Colorectal Disease</i> , 2009 , 24, 165-70	3	39
75	Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. <i>Clinical and Translational Oncology</i> , 2009 , 11, 842-8 ^{3.6}		5
74	A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 965-9	3.5	11
73	Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. <i>British Journal of Clinical Pharmacology</i> , 2009 , 67, 132-4	3.8	8

72	Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 670-4	19.4	3
71	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009 , 101, 715-21	8.7	45 ^o
70	Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). <i>British Journal of Cancer</i> , 2009 , 101, 1261-8	8.7	121
69	Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009 , 66, 327-32	5.9	9
68	Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study. <i>Clinical Lung Cancer</i> , 2009 , 10, 53-7	4.9	11
67	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2622-9	2.2	368
66	Long-Term Outcome of Unresectable Metastatic Colorectal Cancer: Does Adjuvant Chemotherapy Play a Role After Resection?. <i>Annals of Surgery</i> , 2009 , 250, 655	7.8	
65	First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients 2009 , 285-293		
64	Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. <i>British Journal of Cancer</i> , 2008 , 98, 1619-29	8.7	74
63	Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. <i>British Journal of Cancer</i> , 2008 , 99, 716-21	8.7	28
62	Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 7-14	3.8	15
61	Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. <i>Pharmacogenomics Journal</i> , 2008 , 8, 278-88	3.5	93
60	Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 86-90	1.6	2
59	Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1427-34	2.2	113
58	Liver transplantation for metastatic sinonasal undifferentiated carcinoma: a case report. <i>Transplantation Proceedings</i> , 2008 , 40, 3821-2	1.1	4
57	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. <i>Lancet Oncology, The</i> , 2008 , 9, 39-44	21.7	114
56	First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study. <i>British Journal of Cancer</i> , 2008 , 98, 558-63	8.7	7
55	A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2008 , 98, 1312-9	8.7	57

54	5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 2749-55	12.9	47
53	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. <i>Oncologist</i> , 2008 , 13, 1270-5	5.7	197
52	Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. <i>Clinical Cancer Research</i> , 2008 , 14, 1797-803	12.9	170
51	EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. <i>Pharmacogenomics</i> , 2008 , 9, 55-69	2.6	11
50	Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 912-4	8.9	36
49	First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?. <i>Current Opinion in Oncology</i> , 2008 , 20, 459-65	4.2	9
48	Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008 , 134, 1143-9	4.9	46
47	A Pilot Study of a Day One and Eight Every Three Weeks Administration of Docetaxel in Metastatic Cancer Patients. <i>Tumori</i> , 2007 , 93, 145-149	1.7	
46	Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer. <i>British Journal of Cancer</i> , 2007 , 97, 1613-7	8.7	5
45	Chemotherapy intensification. <i>Current Colorectal Cancer Reports</i> , 2007 , 3, 116-122	1	
44	Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2007 , 5, 87-101		2
43	Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1478-86	2.2	883
42	Nuclear factor- κ B tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3930-5	2.2	103
41	Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1816-22	2.2	50
40	Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1247-54	2.2	235
39	Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 58, 585-93	3.5	10
38	Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2006 , 7, 401-5	4.9	16
37	First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2006 , 17, 1249-54	10.3	21

36	Reply to the Letter to the Editor on Cost-opportunity analysis in clinical oncology: from the Wild far-west to a correct integration of the disciplines, avoiding the War of the worlds by D. Tassinari et al. (Ann Oncol 2006; 17: 876). <i>Annals of Oncology</i> , 2006 , 17, 877-878	10.3	
35	Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study. <i>British Journal of Cancer</i> , 2006 , 94, 1263-6	8.7	5
34	Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. <i>Annals of Surgical Oncology</i> , 2006 , 13, 58-65	3.1	140
33	Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer. <i>Tumori</i> , 2006 , 92, 384-388	1.7	12
32	A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 384-95	6.1	52
31	Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. <i>Tumori</i> , 2006 , 92, 384-8	1.7	6
30	Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 362-8	3.2	19
29	Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer. <i>British Journal of Cancer</i> , 2005 , 92, 24-9	8.7	13
28	Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. <i>Annals of Oncology</i> , 2005 , 16, 1243-52	10.3	75
27	A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. <i>Clinical Cancer Research</i> , 2004 , 10, 1657-63	12.9	23
26	First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. <i>Annals of Oncology</i> , 2004 , 15, 1766-72	10.3	82
25	A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. <i>British Journal of Cancer</i> , 2004 , 91, 1996-2004	8.7	151
24	5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 101-5	2.7	2
23	Hypersensitivity reactions related to oxaliplatin (OHP). <i>British Journal of Cancer</i> , 2003 , 89, 477-81	8.7	99
22	Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). <i>Annals of Oncology</i> , 2003 , 14, 1365-72	10.3	24
21	Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. <i>European Journal of Clinical Pharmacology</i> , 2002 , 58, 593-5	2.8	14
20	Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 71, 263-71	6.1	5
19	Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 627-37	6.1	21

18	Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4006-14	2.2	130
17	Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. <i>Annals of Oncology</i> , 2001 , 12, 1301-6	10.3	84
16	Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naïve metastatic colorectal cancer patients. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3456-62	2.2	46
15	5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. <i>Oncology</i> , 2001 , 61, 28-35	3.6	8
14	Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. <i>Oncology</i> , 2000 , 59, 204-9	3.6	6
13	Infusions of fluorouracil and leucovorin: effects of the timing and semi-intermittency of drug delivery. <i>Oncology</i> , 1999 , 57, 195-201	3.6	18
12	Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 44, 159-63	3.5	13
11	Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. <i>Cancer</i> , 1999 , 86, 470-6	6.4	24
10	Pharmacokinetic optimisation of the treatment of cancer with high dose zidovudine. <i>Clinical Pharmacokinetics</i> , 1998 , 34, 173-80	6.2	8
9	Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[¹²³ I]iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer. <i>Acta Oncologica</i> , 1996 , 35, 941-5	3.2	13
8	Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. <i>Journal of Clinical Oncology</i> , 1996 , 14, 729-36	2.2	18
7	Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996 , 19, 592-4	2.7	8
6	Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. <i>Cancer</i> , 1995 , 75, 440-3	6.4	14
5	Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994 , 17, 210-4	2.7	3
4	Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study. <i>Cancer</i> , 1993 , 72, 564-8	6.4	8
3	Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1989 , 12, 43-5	2.7	18
2	Moving-strip abdomino-pelvic radiotherapy after cis-platinum-based chemotherapy and second-look operation. A feasibility study in advanced ovarian cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1988 , 11, 16-20	2.7	8
1	Regional pharmacokinetic selectivity of intraperitoneal cisplatin in ovarian cancer. <i>Oncology</i> , 1988 , 45, 69-73	3.6	3

